E-and P-selectin are inflammation-induced cell adhesion molecules that mediate leukocyte-endothelial cell and leukocyte-platelet interactions. Monoclonal antibodies (MoAbs) specific for either E-selectin or P-selectin are protective in several animal models of inflammatory disease. To generate an MoAb with broader therapeutic potential, MoAbs that bind to both E-and P-selectin were generated by immunization of mice with mouse pre-B Celt lines transfected with human E-and P-selectin. Interestingly, although the only selection criterion was the ability to bind both E-and Pselectin, all three antibodies obtained efficiently block both E-and P-selectin-mediated functions. The inhibited functions include neutrophil or HL-60 cell binding to tumor necro-HE E-, P-AND L-SELECTINS comprise a family of calcium-dependent cell-surface lectins that mediate leukocyte-endothelial cell and leukocyte-platelet adhesive interactions during inflammation.'.' All three selectins have been shown to participate in the initial "rolling" interaction of leukocytes on activated endotheli~m.4.~ This initial interaction precedes and, under flow conditions, is required before P2-integrin (CD18) mediated adhesion and subsequent migration of neutrophils through the endothelium and into inflamed tissue sites?." The expression of P-and E-selectin is regulated, whereas L-selectin is constitutively expressed on the surface of leukocytes. Although P-selectin is constitutively produced by both platelets and endothelial cells, it is stored intracellularly in a-granules or Weibel-Palade bodies for rapid (seconds to minutes) translocation to the cell surface on activation by thrombin, histamine, or other mediators."~'* The expression of endothelial cell E-selectin is controlled at the transcriptional level and thus is induced more slowly. On cultured endothelium, E-selectin expression reaches a peak some 6 to 8 hours after exposure to tumor necrosis factor-a (TNF-a) or interleukin-l (IL-i ) . I 3 , I 4 Depending on the nature of the inflammatory stimuli present and time after initiation of the inflammatory response, either E-or P-selectin may be functionally dominant in promoting leukocyte adhesion to the endothelium and subsequent recruitment into the inflammatory tissue. The results of studies in a variety of animal models of inflammatory disease have previously implicated a role for either E-or P-selectin in mediating the inflammatory damage, depending on the However, recent studies with murine models of inflammation in which E-and P-selectin were blocked simultaneously (B. Wolitzky, presented at the 1994 International Business Communications (IBC) Meeting on Cell Adhesion, May 19, 1994, San Francisco, CA) suggest that the roles of E-and P-selectin in leukocyte recruitment and the resulting inflammatory damage may be more overlapping (redundant) than previously appreciated.
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The E-and P-selectin protein sequences are 62% identical in their lectin domains, 55% in their EGF domains, and 43% in their first SCR domain. Due in part to this high degree of homology, the specificities of the selectins for carbohydrate ligands, while distinct, are ~verlapping.~.~~-** Together these data suggested that blocking antibodies cross-reactive with both E-and P-selectin might be generated. Because a single antibody that blocks both E-and P-selectin might be more broadly useful as a potential therapeutic agent for treating pathologic inflammatory conditions than reagents targeting a single selectin, the E-and P-selectin cross-reacting antibodies, EP-5C7, EP-2C9, and EP-IDS were generated.
Eugene C. Butcher. Sequence analysis of the cDNA clones used to generate these cell lines confirmed their identity, as well as reactivity of the resulting cell lines with appropriate MoAbs.
Chinese hamster ovary (CHO) cells permanently transfected with cDNAs encoding shortened versions of human L-, E-, or P-selectin were generated according to established procedures. Briefly, DNA fragments containing the coding sequences of human E-or P-selectin through the second SCR domain (amino acids 1 through 282 of the mature protein) were prepared by polymerase chain reaction (PCR) from cDNAs obtained from R. Aaron Wamock. The gene for human L-selectin was obtained from R&D Systems. These fragments were then inserted into a pMEM vector, a derivative of pVgl'? that contains the ninth SCR domain of P-selectin as well as the transmembrane domain and a short stretch of the cytoplasmic tail (amino acids 659 through 766). The pMEM vector also contains an SV40 promoter and the mouse glutamine synthetase gene.34 After sequence analysis to ensure validity, the resulting constructs were cotransfected into CHOlKl cells with the pSV2neo vector. After a 2-week selection with 1 g (3418, viable cells were then further selected by culture in glutamine-free Dulbecco's modified Eagle's medium (DMEM) containing 10% dialyzed fetal bovine serum (FBS) and 50 pmoVL methionine s~lfoximine.~~ CH0 cells expressing the appropriate selectins were selected by fluorescence-activated cell sorting (FACS) using appropriate antibodies and subcloned. The resulting cell lines CHOE-"'""''", CHOP-%I"IW and CHOL-seleClin were continuously grown in glutamine-free medium until used for assays.
MoAb production. Balb/c mice were injected intraperitoneally twice with lo7 L1-2E~se'e""" transfectant cells, 2 weeks apart, then 4 weeks later with L1-2p~'e'""" transfectant cells. C57/Ld mice were injected in the footpads with IO' hypotonically lysed L1-2E~'e'e"'" cells, then 3 and 6 days later with lo7 intact L1-2E~'e'eC"" cells, and finally 9 days later with 10' L1-2P"e1e"'" cells. Three days after the last injection, polyethelene glycol-mediated fusion of spleen cells (Balbk) or draining lymph node lymphocytes (C57Ld) with P3X mouse myeloma cells was performed according to standard methods. Hybridomas producing supernatants with reactivity for L1-2E"e'e"'" cells but not with parent L1-2 cells by FACS analysis were subcloned by limiting dilution, grown in serum-free medium containing less than 2% FBS. The E-and P-selectin dual reactive antibodies EP-5C7 (Balblc), EP-2C9, and EP-1 D8 (C57Ld) as well as the E-selectin-specific antibodies E-1E4 and E-2D4 and the Pselectin specific antibody P-5F4 (Balbk), were purified from these supernatants by Protein A-Sepharose (Pierce, Rockford, IL) according to the recommended protocol. The isotypes of EP-5C7, EP-1D8, EP-2C9, P-5F4, and E-IFA antibodies were determined to be IgGl by the use of an Innogenetics Inno-Lia mouse MoAb isotyping kit (Biosource International, Camarillo, CA). E-2D4 was determined to be an IgG2,.
FACS analysis. In general, FACS experiments were performed by incubation of 5 X 10' cells in 0.1 mL FACS buffer (0.1% bovine serum albumin, 10 mmoVL NaN, in phosphate-buffered saline [PBS]) with I O to 100 ng primary antibody for 1 hour at 4°C. After washing, 50 pL of goat F(ab')z antimouse IgG-PE conjugated (TAGO, Burlingame, CA), diluted 1500 in FACS buffer, was added and incubated for 30 minutes before washing and fixation. For preclearing experiments, 10 ng of each antibody was incubated with cells or L1-2p~"1e"'" cells for 1 hour, then supernatants were transferred to a second aliquot of L1-2E~"'eC''" cells or L 1 -2P-uleclin cells. After 1 hour, supernatants were again transferred to a third aliquot of cells. After a final l-hour incubation, supernatants were removed and examined for their reactivity with , or L1-2"""' cells by one-color FACS analysis as described above. All FACS analyses were performed on a Becton Dickinson FACScan (San Jose, CA), according to standard procedures. and ~1-2P-sel"lin 107 ~1-2E-see'e~tm Platelet-HL-60 rosette assay. This assay was performed as previously described." Normal human blood was collected with sodium citrate as anticoagulant, and platelet-rich plasma (PRP) was prepared by centrifugation at 250g for 10 minutes. Platelets were isolated from PRP by centrifugation at 1,OOOg for 20 minutes and were resuspended at 3 X 108/mL in PBS, pH 7.2. MoAbs (1 pg in 20 pL) were added to 20 pL platelets, in some cases with normal human thrombin (0.3 UlmL). After 45 minutes, 20 p L HL-60 cells ( IOh/ mL in PBS) were added and incubated for an additional 45 minutes. Bound platelets were fixed to HL-60 cells by addition of glutaraldehyde to 1.25%. At least 100 HL-60 cells for each sample were observed microscopically and the number of cells with bound platelets (>2 platelets per HL-60 cell) determined.
Antibody competition.
Purified EP-5C7 was isolated from serum-free supernatants by Protein A affinity chromatography (Pierce) and was conjugated to fluorescein isothiocyanate (Molecular Probes) according to standard procedures. Approximately IO7 normal thrombin-activated human platelets (prepared as indicated above and resuspended in FACS buffer) were incubated with an excess amount ( I pg) of various E-or P-selectin-specific or E/P-selectin dual-specific antibodies or control antibodies for 5 minutes before the addition of a limiting amount (185 ng) of FITC-conjugated EP-5C7 for I hour. Platelets were then washed, fixed, and analyzed by FACS analysis as described above. Similar experiments were performed using 5 X mL total volume. 
RESULTS
MoAbs EP-5C7, EP-2C9, and EP-ID8 are single antibodies recognizing both E-and P-selectin. Three MoAbs recognizing both P-and E-selectin were generated and selected by their ability to bind L1-2 pre-B cells transfected with For personal use only. on October 23, 2017. by guest www.bloodjournal.org From either P-selectin or E-selectin, and not parent L1-2 cells (data not shown). Although the hybridomas producing these antibodies were cloned by limiting dilution, to ensure that the reactivity to both E-and P-selectin was due to a single antibody and not a mixture of two separate antibodies, preclearing studies were also done. These were performed by incubating a limiting quantity of each antibody with excess numbers of L1-2""1e"i" cells to deplete the E-selectin-specific reactivity or L1-2p~"1"t'n cells to deplete the P-selectinspecific reactivity, then testing the resulting antibody solutions for reactivity with CHOP-Se1eCtin or CHOE-SeleCtin cells. As shown in Fig 1, preincubation of show the corresponding staining after preclearing. These results would be obtained only if the antibody solution contained a single antibody that could bind both selectins and not if the solution were a mixture of two separate antibodies, one reactive with E-selectin and one reactive with P-selectin. Similar results were found for EP-2C9 and EP-1D8, whereas the reactivity of the control antibody WAPS 12.2 with single reactivity for P-selectin could be removed by preclearing cells but not with L1-2ese1ectin cells (not shown).
Reactivity of MoAbs with natural forms of human E-and P-selectin but not L-selectin. To confirm that the crossreacting EP-selectin-specific antibodies recognize naturally occuring forms of E-and P-selectin and not just the recombinant forms, TNF-a-activated HUVEC which express Eselectin, as well as thrombin-activated normal human platelets which express P-selectin, were tested by FACS analysis. As shown in Fig 2, only TNF-a activated HUVEC (histograms labeled +TNFa) and not control HUVEC (labeled -TNFa) react with EP-5C7 (right). TNF-a activated HU-VEC express E-selectin as indicated by their reactivity with the anti-E-selectin antibody H18/7 (shown in Fig 2a) but the of CHOP-selectin CHOE-selectin with L 1 -2P-SdeCIln do not express appreciable amounts of P-selectin as indicated by lack of reactivity with anti-P-selectin antibody WAPS 12.2 (data not shown). Thrombin-activated platelets, which do express high levels of P-selectin (detected by WAPS 12.2, Fig 3a) also react strongly with EP-5C7 (Fig 3b) . EP-5C7 does not react with CHOL-selectin cells, L1-2L""'""'" cells, or with normal peripheral blood leukocytes, showing that its reactivity is restricted to the E-and P-selectins. The antibodies EP-2C9 and EP-1D8 were also tested and found to react similarly. E-/P-selectin cross-reacting antibodies block E-selectin mediated functions. Antibodies were tested for the ability to block neutrophil binding to 4-hour TNF-a-activated HU-VEC. Normal human neutrophils were added to TNF-aactivated HUVEC preincubated with antibody or media alone. After washing, bound neutrophils were counted and the number of neutrophils binding to the activated HUVEC was decreased 71% by preincubation with EP-5C7 (Fig 4) . This compared favorably with blocking by the E-selectinspecific antibodies H18/7 and E-1E4 (both 68%). Neutrophil binding was also inhibited by EP-2C9 and EP-ID8 but not significantly by the control antibody. Because HUVEC can also express P-selectin (although not detectable by FACS analysis under these conditions, data not shown), to confirm the ability of EP-SC7 to block E-selectin function, assays were performed with neutrophils and C H 0 cells transfected with E-selectin. EP-SC7 was found to block adhesion under these conditions 77% (Fig S ) , comparably to the E-selectin blocking antibody E-1 E 4 , confirming its blocking specificity for E-selectin. The EP-2C9 and EP-ID8 antibodies also blocked similarly, while the control antibody had no effect (Fig S ) . 
E-/P-selectirl dual-reactive antibodies block P-selectinmediatedfinctions.
Antibodies were tested for their ability to block the P-selectin-dependent rosetting of activated platelets with HL-60 cells. As shown in Fig 6, EP-SC7 , EP-2C9, and EP-ID8 antibodies block rosetting and compare favorably with inhibition by the P-selectin blocking antibody WAPS 12.2, while the control antibody had no effect in this assay. EP-SC7, EP-2C9, and EP-ID8 also block HL-60 adhesion to CHOP"r'"'"' cells (Fig 7) , whereas control antibodies have no effect.
E-/P-selectin dual-reactive antibodies compete f o r the scrme ( o r overlappir@ epitope. Thrombin-activated plate- Dual-reactive E-/P-selectin-specific antibodies block HL-60 adhesion t o P-selectin transfectants. Fluorescently labeled HL-60 cells were incubated with CHO""' "" cells in the presence of antibodies (10 pg/mL) or media, as indicated. After washing, adherent neutrophils were counted microscopically. The results from a representative experiment performed with each sample in quadruplicate (+SD) are shown.
For 
Antibodies designated as function blocking demonstrate the ability to block in the appropriate E-or P-selectin-dependent adhesion assays as described in Materials and Methods.
t Ability to block binding to P-selectin was measured by binding of a limiting amount of FITC-conjugated EP-5C7 to thrombin-activated platelets, or L1-2p~se'e""" cells in the presence of a fivefold excess of competitor, measured by FACS analysis, as described in Materials and Methods. I+) Indicates the fluorescence signal was reduced to background levels (at least an 80% decrease of the mean fluorescence intensity that was obtained in the absence of competitor). (-1 Indicates no change (<20% effect on mean fluorescence intensity) as measured by FACS analysis. +Ability to block binding to E-selectin was measured by binding of FITC-conjugated EP-5C7 to L1-2E"e'e""" or CHOE-Se'eC"" cells in the presence of a fivefold excess of competitor.
lets or L 1 -2E-sc' ectln cells were incubated with a limiting amount of LlTC-conjugated EP-5C7 in the presence of excess amounts of unconjugated antibodies as competitors as shown in Table 1 . Interestingly, both EP-2C9 and EP-ID8 compete with EP-5C7 for reactivity with both E-and Pselectin, suggesting that they bind a similar or overlapping epitope. Among a number of antibodies specific for E-selectin, including blocking (H18/7, E-1E4, and BBIG-E4) as well as nonblocking antibodies (E-2D4), only BBIG-E4 was found to block EP-5C7 binding to E-selectin. This antibody has been previously shown to react with the lectin domain of E-selectin,36 suggesting that the EP-5C7 epitope is also within the lectin domain. Among the P-selectin-specific antibodies tested including blocking (WAPS 12.2 and GA6) as well as nonblocking antibodies (WAPS 14. I , ACl.2, AK-6, and P-5F4), only WAPS 12.2 was found to block EP-5C7 binding to platelets or cells. Although not directly tested here, it is unlikely the epitope recognized by EP-5C7 is related to the calcium-dependent epitopes recognized by the blocking P-selectin antibodies GI, G2, and G3 described by Geng et al,'7 because the recognition of Pselectin (on platelets, CHOP~sr'ec'in and ~1-2P-'electin cells) by these antibodies does not differ in the presence of 2 mmoll L CaClz or 5 mmol/L EDTA in the staining buffer (data not shown). Experiments with chimeric and deleted selectin proteins to more precisely localize the epitopes of the ERselectin specific antibodies are ongoing and will be presented elsewhere.
DISCUSSION
Three MoAbs were generated that bind human P-and Eselectin but not L-selectin. All three antibodies block P-and E-selectin-mediated functions including neutrophil and HL-60 adhesion to TNF-a-activated HUVEC, E-or P-selectin transfectant cell lines, and also the P-selectin-dependent rosetting of HL-60 cells by platelets. The ability of all three antibodies to efficiently block both E-selectin and P-selectin-mediated functions was somewhat surprising because blocking epitopes on these selectins are not particularly immunodominant in mice. Indeed it appears that most antibodies selected for their reactivity with P-selectin, generated by ourselves as well as other^^'.^^ (and unpublished observations, C.F., E.B., May 1994), do not block function. By selecting for an antibody that recognizes both selectins, we appear to have selected for a functional epitope.
One other MoAb has been described with affinity for multiple selectins, the EL-246 antibody reactive with human Eand L-selectin. This antibody has potent blocking capacity for both E-and L-selectin-mediated binding interaction^,^" supporting the finding that common structural features shared between selectins are functionally important. However, the EL-246 epitope is located in the first SCR domain of E-and L-selectin, whereas the novel antibodies described here recognize an epitope within the lectin domain of E-and P-selectin. MoAb BBIG-E4, an antibody previously mapped to the lectin domain of E-selectin," was able to compete with EP-5C7 for binding to E-but not P-selectin. Preliminary experiments demonstrating EP-5C7 recognition of a chimeric selectin composed of the lectin portion of E-selectin and the EGF and SCR domains of L-selectin support this conclusion. The observation that antibodies directed against E-and L-selectin (EL-246) or E-and P-selectin (EP-5C7, EP-2C9, and EP-1D8) are potent blocking antibodies despite being directed to completely separate domains suggests that functionally important epitopes of homologous proteins can be targetted by selecting for antibodies reactive with both proteins.
In vivo animal studies have shown the involvement of either E-or P-selectin in neutrophil-mediated inflammatory damage, depending on the initiating stimuli. In an IgG complex model of lung injury in the rat, antibodies to E-selectin protected against neutrophil-mediated damage." In contrast, antibodies to P-selectin were found to protect against acute lung injury induced by intravenous injection of cobra venom factor," as well as in a rat model of systemic endotoxemia." Antibodies to P-selectin were also found to be protective in a cat model of myocardial ischemia and reperfusion injury.'' In human patients with inflammatory diseases, the relative roles of E-or P-selectin may be less distinct. The results of recent studies in mice by Barry Wolitsky et a1 (personal communication, September 1994) suggest significant redundancy in the usage of E-and P-selectin in three murine models of inflammation: acute peritonitis, delayed-type hypersensitivity, and lipopolysaccharide-induced acute lung injury. Inhibition of either P-or E-selectin (with specific
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MoAbs, or using P-selectin or E-selectin knock-out mice) had either moderate or undetectable protective effects in these models. In contrast, inhibition of both P-and E-selectin resulted in dramatic attenuation of the inflammatory responses tested. The dual-reactive E-P-selectin-specific antibodies described here, which are capable of blocking both E-and P-selectin-mediated functions, would also be expected to be more effective than antibodies directed towards only E-or P-selectin in treating a variety of inflammatory disorders in humans. When humanized, such an antibody might provide a potent, nontoxic, anti-inflammatory therapeutic with enhanced half-life in vivo, thus potentially applicable to treating a variety of inflammatory conditions, including certain chronic diseases with episodic symptoms.
